Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi, Multiple Sclerosis
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
Biomarkers for predicting multiple sclerosis progression identified
Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the development of more personalized treatment strategies.
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed increased disability improvement,
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
New multiple sclerosis drug by Sanofi delays progressive form of disease by 31 per cent in trial
Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Aubagio’s patent protection
FierceBiotech
2d
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
MedPage Today
1d
Women With MS Less Likely to Receive Treatment Than Men
Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...
STAT
9d
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...
Multiple Sclerosis News Today
3d
ECTRIMS 2024: High-dose vitamin D can help delay progression to MS
High-dose cholecalciferol (vitamin D) is safe and can nearly double the time it takes for clinically isolated syndrome to ...
Medpage Today on MSN
5d
Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse Outcomes
Higher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...
PHILADELPHIA.Today on MSN
2d
Local Multiple Sclerosis Advocate Honored With State Citation
Bucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...
Medscape
9d
Does Multiple Sclerosis Protect Against Alzheimer's?
Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...
4d
on MSN
California’s cap on health care costs is the nation’s strongest. But will patients notice?
Vickie Villegas had to pay $3,000 out-of-pocket every time she was treated for multiple sclerosis, a disease that attacks the ...
3d
on MSN
Key biomarkers identified for predicting disability progression in multiple sclerosis
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...
Medscape
2d
High-Dose Vitamin D Linked to Lower Disease Activity in CIS
Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Sanofi
MS
tolebrutinib
Mississippi
IBD
Feedback